Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)
China · Delayed Price · Currency is CNY 37.02
-0.93 (-2.45%)
At close: Jun 2, 2026
SHE:301520 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Net Income | 24.32 | 36.43 | 85.53 | 108.09 | 98.73 | 81.87 |
Depreciation & Amortization | 15.69 | 15.69 | 15.12 | 9.7 | 5.49 | 3.99 |
Other Amortization | 4.11 | 4.11 | 3.86 | 2.69 | 1.83 | 1.71 |
Loss (Gain) From Sale of Assets | 0.06 | 0.06 | -0.02 | - | - | 0 |
Asset Writedown & Restructuring Costs | 0.48 | 0.48 | 0.04 | 0.02 | 2.3 | 0.91 |
Loss (Gain) From Sale of Investments | -31.92 | -31.92 | -28.19 | -6.22 | -3.18 | -1.85 |
Provision & Write-off of Bad Debts | 6.88 | 6.88 | 5.69 | 3.97 | - | 0.79 |
Other Operating Activities | 24.86 | 0.25 | 0.13 | 0.14 | 0 | 0.05 |
Change in Accounts Receivable | -37.81 | -37.81 | -48.76 | -66.1 | -44.97 | -25.57 |
Change in Inventory | 1.09 | 1.09 | -1.29 | -0.22 | -0.26 | 0.2 |
Change in Accounts Payable | -2.83 | -2.83 | 13.41 | 16.32 | 11.44 | -6.56 |
Change in Other Net Operating Assets | 1.2 | 1.2 | - | - | - | - |
Operating Cash Flow | 4.57 | -7.92 | 46.84 | 71.92 | 72.32 | 55.43 |
Operating Cash Flow Growth | -84.45% | - | -34.87% | -0.55% | 30.47% | 17.64% |
Capital Expenditures | -20.17 | -19.22 | -41.82 | -85.97 | -50.7 | -15.6 |
Sale of Property, Plant & Equipment | 0.08 | 0.08 | 0.09 | - | - | - |
Investment in Securities | -84.02 | 16.16 | -66.49 | -949.1 | - | - |
Other Investing Activities | 14.52 | 17.51 | 21.16 | 2.37 | 3.18 | 1.85 |
Investing Cash Flow | -89.59 | 14.53 | -87.06 | -1,033 | -47.52 | -13.74 |
Long-Term Debt Repaid | - | - | - | -0.03 | -0.12 | -0.09 |
Net Debt Issued (Repaid) | - | - | - | -0.03 | -0.12 | -0.09 |
Issuance of Common Stock | - | - | - | 1,053 | - | - |
Repurchase of Common Stock | -12.39 | -12.39 | -2.84 | - | - | - |
Common Dividends Paid | -1.31 | -23.21 | -31.14 | - | - | - |
Other Financing Activities | 4.9 | - | - | -24.79 | - | - |
Financing Cash Flow | -8.81 | -35.6 | -33.98 | 1,028 | -0.12 | -0.09 |
Net Cash Flow | -93.83 | -29 | -74.2 | 67.34 | 24.68 | 41.6 |
Free Cash Flow | -15.6 | -27.14 | 5.02 | -14.05 | 21.63 | 39.84 |
Free Cash Flow Growth | - | - | - | - | -45.71% | -1.01% |
Free Cash Flow Margin | -6.68% | -9.90% | 1.32% | -4.11% | 8.29% | 18.87% |
Free Cash Flow Per Share | -0.23 | -0.41 | 0.07 | -0.26 | 0.43 | 0.80 |
Cash Income Tax Paid | 1.55 | 2.46 | 11.64 | 14.78 | 16.67 | 18.5 |
Levered Free Cash Flow | 0.65 | -14.9 | 22.45 | -114.45 | 2.22 | 21.74 |
Unlevered Free Cash Flow | 0.65 | -14.9 | 22.45 | -114.45 | 2.23 | 21.75 |
Change in Working Capital | -39.91 | -39.91 | -35.32 | -46.46 | -32.86 | -32.04 |